A 3-DNA Methylation Signature As a Novel Prognostic Biomarker in Patients with Sarcoma by Bioinformatics Analysis

Xiao-Wei Wang,Qi Sun,Shi-Bin Xu,Chao Xu,Chen-Jie Xia,Qi-Ming Zhao,Hua-Hui Zhang,Wei-Qiang Tan,Lei Zhang,Shu-Dong Yao
DOI: https://doi.org/10.1097/md.0000000000026040
IF: 1.6
2021-01-01
Medicine
Abstract:Background: Tumor-specific DNA methylation can potentially be a useful indicator in cancer diagnostics and monitoring. Sarcomas comprise a heterogeneous group of mesenchymal neoplasms which cause life-threatening tumors occurring throughout the body. Therefore, potential molecular detection and prognostic evaluation is very important for early diagnosis and treatment. Methods: We performed a retrospective study analyzing DNA methylation of 261 patients with sarcoma from The Cancer Genome Atlas (TCGA) database. Cox regression analyses were conducted to identify a signature associated with the overall survival (OS) of patients with sarcoma, which was validated in a validation dataset. Results: Three DNA methylation signatures were identified to be significantly associated with OS. Kaplan-Meier analysis showed that the 3-DNA methylation signature could significantly distinguish the high- and low-risk patients in both training (first two-thirds) and validation datasets (remaining one-third). Receiver operating characteristic (ROC) analysis confirmed that the 3-DNA methylation signature exhibited high sensitivity and specificity in predicting OS of patients. Also, the Kaplan-Meier analysis and the area under curve (AUC) values indicated that the 3-DNA methylation signature was independent of clinical characteristics, including age at diagnosis, sex, anatomic location, tumor residual classification, and histological subtypes. Conclusions: The current study showed that the 3-DNA methylation model could efficiently function as a novel and independent prognostic biomarker and therapeutic target for patients with sarcoma.
What problem does this paper attempt to address?